-+ 0.00%
-+ 0.00%
-+ 0.00%

TRIGEMX BIO ANNOUNCES $94M FINANCING AND INITIATION OF PHASE 3 TRIALS FOR ELISMETREP, A POTENTIAL FIRST-IN-CLASS TREATMENT FOR MIGRAINE

Reuters·10/01/2026 13:02:19

Please log in to view news